natgillin/translations-raw huggingface dataset:
I et studie med 880 randomiserede patienter, der ikke responderede tilstrækkeligt på behandling med aliskiren 300 mg, viste kombinationen af aliskiren/ hydrochlorthiazid 300 mg/ 25 mg systoliske/ diastoliske blodtryksreduktioner på 15, 8/ 11, 0 mmHg, hvilket var signifikant større end for aliskiren 300 mg monoterapi.
In a study in 880 randomised patients not adequately responsive to aliskiren 300 mg treatment, the combination of aliskiren/ hydrochlorothiazide 300 mg/ 25 mg produced systolic/ diastolic blood pressure reductions of 15.8/ 11.0 mmHg, which were significantly greater than aliskiren 300 mg monotherapy.
I et studie med 722 randomiserede patienter, der ikke responderede tilstrækkeligt på behandling med hydrochlorthiazid 25 mg, viste kombinationen af aliskiren/ hydrochlorthiazid 300 mg/ 25 mg systoliske/ diastoliske blodtryksreduktioner på 16, 78/ 10, 7 mmHg, hvilket var signifikant større end for hydrochlorthiazid 25 mg monoterapi.
In a study in 722 randomised patients not adequately responsive to hydrochlorothiazide 25 mg treatment, the combination of aliskiren/ hydrochlorothiazide 300 mg/ 25 mg produced systolic/ diastolic blood pressure reductions of 16.78/ 10.7 mmHg, which were significantly greater than hydrochlorothiazide 25 mg monotherapy.
I et andet klinisk forsøg blev Rasilez HCT' s virkning og sikkerhed ligeledes vurderet i 489 overvægtige, hypertensive patienter, der ikke responderede på hydrochlorthiazid 25 mg (baseline systolisk/ diastolisk blodtryk 149, 4/ 96, 8 mmHg).
In another clinical trial, the efficacy and safety of Rasilez HCT were also assessed in 489 obese hypertensive patients who did not respond to hydrochlorothiazide 25 mg (baseline systolic/ diastolic blood pressure 149.4/ 96.8 mmHg).
I denne population, der er svær at behandle, gav Rasilez HCT en blodtryksreduktion (systolisk/ diastolisk) på 15, 8/ 11, 9 mmHg sammenlignet med 15, 4/ 11, 3 mmHg for irbesartan/ hydrochlorthiazid, 13, 6/ 10, 3 mmHg for amlodipin/ hydrochlorthiazid og 8, 6/ 7, 9 mmHg for hydrochlorthiazid monoterapi med samme sikkerhedsprofil som for
In this difficult-to-treat population, Rasilez HCT provided a blood pressure reduction (systolic/ diastolic) of 15.8/ 11.9 mmHg compared to 15.4/ 11.3 mmHg for irbesartan/ hydrochlorothiazide, 13.6/ 10.3 mmHg for amlodipine/ hydrochlorothiazide and 8.6/ 7.9 mmHg for hydrochlorothiazide monotherapy, with similar safety to hydrochlorothiazide monotherapy.
I et studie med 183 randomiserede patienter med svær hypertension (middel diastolisk blodtryk i siddende stilling ≥ 105 og < 120 mmHg) blev det vist, at et aliskiren- baseret behandlingsregime med valgfrit tillæg af 25 mg hydrochlorthiazid er sikkert og effektivt til reduktion af blodtrykket.
In a study in 183 randomised patients with severe hypertension (mean sitting diastolic blood pressure ≥ 105 and < 120 mmHg), aliskiren treatment regimen with optional addition of hydrochlorothiazide 25 mg was shown to be safe and efficacious in reducing blood pressure.
Aliskiren Absorption Efter oral absorption nås maksimale plasmakoncentrationer af aliskiren efter 1- 3 timer.
Aliskiren Absorption Following oral absorption, peak plasma concentrations of aliskiren are reached after 1-3 hours.
Fordeling Efter intravenøs administration er det gennemsnitlige distributionsvolumen omkring 135 liter, hvilket indikerer, at aliskiren distribueres langt ind i det ekstravaskulære rum.
Distribution Following intravenous administration, the mean volume of distribution at steady state is approximately 135 litres, indicating that aliskiren distributes extensively into the extravascular space.
Aliskiren udskilles hovedsageligt som et uændret stof i fæces (oral radioaktiv dosisgenfinding = 91%).
Aliskiren is mainly eliminated as unchanged compound in the faeces (oral radioactive dose recovery = 91%).
Linearitet Eksponeringen for aliskiren øgedes lidt mere end proportionalt sammenlignet med stigningen i dosis.
Linearity Exposure to aliskiren increased slightly more than in proportion to the increase in dose.
Efter administration af en enkelt dosis i intervallet 75 til 600 mg, resulterede en fordobling i dosis i en ~2, 3 og 2, 6 gange stigning i respektivt AUC og Cmax.
After single dose administration in the dose range of 75 to 600 mg, a 2-fold increase in dose results in a ~2.3 and 2.6-fold increase in AUC and Cmax, respectively.
2 timer) med lignende absorptionskarakteristika for både suspensions - og tabletformulering.
Hydrochlorothiazide Absorption The absorption of hydrochlorothiazide, after an oral dose, is rapid (Tmax about 2 h), with similar absorption characteristics for both suspension and tablet formulations.
Absolut biotilgængelighed af hydrochlorthiazid er 60- 80% efter oral indgivelse.
Absolute bioavailability of hydrochlorothiazide is 60-80% after oral administration.
Det er blevet rapporteret, at samtidigt indtag af mad både øger og reducerer hydrochlorthiazids systemiske tilgængelighed sammenlignet med den fastende tilstand.
Concomitant administration with food has been reported to both increase and decrease the systemic availability of hydrochlorothiazide compared with the fasted state.
Omfanget af disse virkninger er lille og har kun lille klinisk betydning.
The magnitude of these effects is small and has little clinical importance.
Fordeling Det tilsyneladende distributionsvolumen er 4- 8 l/ kg.
Distribution The apparent volume of distribution is 4-8 l/ kg.
Cirkulerende hydrochlorthiazid er bundet til serumproteiner (40- 70%), hovedsagelig serumalbumin.
Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin.
3 gange mere end niveauet i plasma.
Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.
Metabolisering og udskillelse Efter oral indgivelse udskilles > 95% af den absorberede dosis som en uændret forbindelse i urinen.
Metabolism and elimination After oral administration, > 95% of the absorbed dose being excreted as unchanged compound in the urine.
Distributions - og eliminationskinetik er generelt blevet beskrevet vha. en bieksponentiel henfaldsfunktion med en terminal halveringstid på 6- 15 timer.
The distribution and elimination kinetics have generally been described by a bi-exponential decay function, with a terminal half-life of 6-15 h.
13 Linearitet Stigningen i middel- AUC er lineær og dosisproportional i det terapeutiske område.
Linearity The increase in mean AUC is linear and dose proportional in the therapeutic range.
Aliskiren/ hydrochlorthiazid Efter oral indgivelse af Rasilez HCT- tabletter er tiden for middel peak- plasmakoncentrationen under 1 time for aliskiren og 2, 5 timer for hydrochlorthiazid.
13 Aliskiren/ hydrochlorothiazide Following oral administration of Rasilez HCT tablets, the median peak plasma concentration time is within 1 hour for aliskiren and 2.5 hours for hydrochlorothiazide.
Karakteristika hos patienter Rasilez HCT har vist sig effektiv som antihypertensiv behandling en gang daglig til voksne patienter uanset køn, alder, BMI og etnicitet.
Characteristics in patients Rasilez HCT has been shown to be effective as a once-a-day antihypertensive treatment in adult patients, regardless of gender, age, body mass index and ethnicity.
Aliskirens og hydrochlorthiazids farmakokinetik blev ikke signifikant påvirket hos patienter med let til moderat leversygdom.
The pharmacokinetics of aliskiren and hydrochlorothiazide are not significantly affected in patients with mild to moderate liver disease.
4. 3).
However, due to its hydrochlorothiazide component, Rasilez HCT is contraindicated in patients with severe hepatic impairment (see section 4.3).
4. 4 og 4. 2).
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 4.2).
Der er ingen tilgængelige data for Rasilez HCT hos patienter med stærkt nedsat nyrefunktion (GFR < 30 ml/ min/ 1, 73 m2).
No data are available for Rasilez HCT in patients with severe renal impairment (GFR < 30 ml/ min/ 1.73 m2).
Som forventet af en forbindelse, der udskilles næsten udelukkende via nyrerne, har nyrefunktionen imidlertid en markant virkning på hydrochlorthiazids kinetik.
However, as expected for a compound which is cleared almost exclusively via the kidneys, renal function has a marked effect on the kinetics of hydrochlorothiazide.
4. 3).
Therefore, Rasilez HCT is contraindicated in patients with severe renal impairment (GFR < 30 ml/ min/ 1.73 m2) (see section 4.3).
Der kræves ingen justering af initialdosen for ældre patienter.
No initial dose adjustment of Rasilez HCT is required in elderly patients.
Intet karcinogent potentiale blev observeret i et 2- årigt rottestudie og i et 6- måneders studie af transgene mus.
No carcinogenic potential for aliskiren was detected in a 2-year rat study and a 6-month transgenic mouse study.
Aliskiren havde ikke noget mutagent potentiale, embryo- føtal toksicitet eller teratogenicitet.
Aliskiren was devoid of any mutagenic potential, embryo-foetal toxicity or teratogenicity.
Prækliniske evalueringer, der støtter administrationen af hydrochlorthiazid til mennesker, omfattede in vitro - genotoksicitetsanalyser og reproduktionstoksicitets - og carcinogenicitetsstudier af gnavere.
Preclinical evaluations to support the administration of hydrochlorothiazide in humans included in vitro genotoxicity assays and reproductive toxicity and carcinogenicity studies in rodents.
De observerede resultater i 2- ugers og 13- ugers toksicitetsstudier er i overensstemmelse med de resultater, som tidligere er observeret for aliskiren og hydrochlorthiazid monoterapi.
The findings observed in the 2-week and 13-week toxicity studies were consistent with those observed previously with aliskiren or hydrochlorothiazide monotherapies.
Der er observeret øget cellulær vakuoledannelse i binyrens zona glomerulosa i 13- ugers toksicitetsstudiet hos rotter.
Increased cellular vacuolation of the adrenal gland zona glomerulosa was observed during the 13-week toxicity study in rats.
Der er intet bevis for, at disse resultater var forøget i aliskiren/ hydrochlorthiazid -
There was no evidence that this finding was enhanced in the aliskiren/ hydrochlorothiazide combination as it was only apparent at a minimal severity in all animals.
Cellulose, mikrokrystallinsk Crospovidon Laktosemonohydrat Hvedestivelse Povidon Magnesiumstearat Silica, kolloid vandfri Talcum
Cellulose microcrystalline Crospovidone Lactose monohydrate Wheat starch Povidone Magnesium stearate Silica colloidal anhydrous Talc
Talcum Hypromellose Macrogol Titandioxid (E171)
Talc Hypromellose Macrogol Titanium dioxide (E171)
Alu- blisterpakninger af PA/ Alu/ PVC:
PA/ Alu/ PVC – Alu blisters:
Alu- blisterpakninger af PVC/ polychlortrifluorethylen (PCTFE):
PVC/ polychlorotrifluoroethylene (PCTFE) – Alu blisters:
Rasilez HCT 150 mg/ 25 mg filmovertrukne tabletter
Rasilez HCT 150 mg/ 25 mg film-coated tablets
Hver tablet indeholder 50 mg laktosemonohydrat og 49 mg hvedestivelse.
Each tablet contains 50 mg lactose monohydrate and 49 mg wheat starch.
Svagt gul, udadbuet, oval, filmovertrukken tablet, præget med ” CLL ” på den ene side og ” NVR ” på den anden.
Pale yellow, biconvex, ovaloid film-coated tablet imprinted with “ CLL” on one side and “ NVR” on the other.
Rasilez HCT 150 mg/ 25 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt behandlet med aliskiren 150 mg eller hydrochlorthiazid 25 mg anvendt alene eller med Rasilez HCT 150 mg/ 12, 5 mg.
Rasilez HCT 150 mg / 25 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 150 mg or hydrochlorothiazide 25 mg alone or by Rasilez HCT 150 mg/ 12.5 mg.
17 Hvis blodtrykket ikke er under kontrol efter 2- 4 ugers behandling kan dosis titreres op til en maksimal daglig dosis på 300 mg/ 25 mg Rasilez HCT.
If blood pressure remains uncontrolled after 2-4 weeks of therapy, the dose may be titrated up to a maximum of Rasilez HCT 300 mg/ 25 mg daily.
Dosering ved erstatningsterapi Patienter, som får aliskiren og hydrochlorthiazid fra hver sin tablet, kan for nemhedens skyld skifte til Rasilez HCT med den samme dosis af hver komponent.
17 Posology as substitution therapy For convenience, patients receiving aliskiren and hydrochlorothiazide from separate tablets may be switched to a fixed combination tablet of Rasilez HCT containing the same component doses.
18 Intravaskulær væskemangel Symptomatisk hypotension kan forekomme hos patienter med væske - og/ eller saltmangel som et resultat af kraftig diuretikabehandling, diæt med begrænset saltindtag, diarré eller opkastning.
Intravascular volume depletion Symptomatic hypotension may occur in patients who are volume and/ or sodium depleted as a result of vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Elektrolytubalance Som for enhver patient, der modtager diuretikabehandling, skal der foretages en regelmæssig bestemmelse af serumelektrolytter med passende intervaller.
18 Electrolyte imbalance As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.
19 Der er ingen klinisk erfaring med Rasilez HCT til patienter med nedsat leverfunktion.
There is no clinical experience with Rasilez HCT in patients with hepatic impairment.
Moderate P- gp- hæmmere Samtidig administration af 300 mg aliskiren og 200 mg ketoconazol resulterede i en 76% stigning i aliskirens AUC, men P- gp- hæmmere som ketoconazol kan forventes at øge vævskoncentrationerne mere end plasmakoncentrationerne.
19 Moderate P-gp inhibitors Co-administration of aliskiren 300 mg with ketoconazole 200 mg resulted in a 76% increase in aliskiren AUC but P-gp inhibitors such as ketoconazole are expected to increase tissue concentrations more than plasma concentrations.
Omvendt, baseret på erfaringerne med anvendelsen af andre lægemidler, som påvirker renin- angiotensin- systemet (RAS), kan samtidig 20 brug af kaliumbesparende diuretika, kaliumtilskud, kaliumholdige salterstatninger eller andre lægemidler, som øger koncentrationen af kalium i serum (f. eks. heparin), føre til stigninger serumkalium.
Conversely, based on experience with the use of other medicinal products that blunt the renin-angiotensin system (RAS), concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin sodium) may lead to increases in serum potassium.
Lægemidler, der påvirkes af serumkaliumforstyrrelser:
20 Medicinal products affected by serum potassium disturbances:
21 Furosemid:
Furosemide:
Hos visse patienter med svækket nyrefunktion (dehydrerede patienter eller ældre patienter) kan samtidig administration af aliskiren og NSAID medføre en forværring af nyrefunktion, inklusive mulighed for akut nyresvigt, som sædvanligvis er reversibel.
21 with NSAIDs may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
Thiazider kan reducere cytotoksiske
Thiazides may reduce the renal excretion of cytotoxic medicinal products (e. g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
22 lægemidlers renale udskillelse (f. eks. cyclofosfamid, methotrexat) og potentiere deres myelosuppressive virkninger.
22 4.6 Pregnancy and lactation
Langvarig eksponering over for thiazider i 3. trimester af graviditeten kan reducere moderens plasmamængde samt den uteroplacentale blodstrøm, hvilket kan forårsage føto- placental iskæmi og væksthæmning.
Prolonged exposure to thiazides during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a foeto-placental ischaemia and growth retardation.
23 Diarré:
23 Serum potassium:
Yderligere oplysninger om individuelle komponenter Bivirkninger, der tidligere er blevet indberettet for en af de individuelle komponenter, kan forekomme med Rasilez HCT, selvom de ikke er blevet observeret i kliniske forsøg.
Additional information on individual components Adverse reactions previously reported with one of the individual components may occur with Rasilez HCT even if not observed in clinical trials.
4. 4).
Hydrochlorothiazide Adverse events (regardless of relationship to medicinal product) reported with the use of hydrochlorothiazide alone include:
24 Hydrochlorthiazid Rapporterede bivirkninger (uanset forhold til lægemidlet) ved anvendelsen af hydrochlorthiazid alene omfatter:
24 Blood and lymphatic system disorders
Rasilez HCT kombinerer to antihypertensive komponenter til kontrol af blodtryk hos patienter med essentiel hypertension:
25 Rasilez HCT combines two antihypertensive compounds to control blood pressure in patients with essential hypertension:
26 Hydrochlorthiazid Thiaziddiuretikas virkningspunkt er primært i nyrens tubulus contortus distalis.
Hydrochlorothiazide The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule.
Thiaziders virkningsmåde er gennem hæmning af Na+Cl - symporteren ved at konkurrere om Cl- bindingsstedet, hvorved elektrolytreabsorptionsmekanismerne påvirkes: ved direkte at øge natrium - og kloridudskillelse i omtrent lige omfang og indirekte ved, at denne diuretiske virkning reducerer plasmavolumen med efterfølgende stigninger i plasmareninaktivitet, aldosteronudskillelse og urinkaliumtab samt en reduktion i serumkalium.
26 approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.
27 hydrochlorthiazid monoterapi.
27 5.2 Pharmacokinetic properties
28 Linearitet Stigningen i middel- AUC er lineær og dosisproportional i det terapeutiske område.
Linearity The increase in mean AUC is linear and dose proportional in the therapeutic range.
Aliskiren/ hydrochlorthiazid Efter oral indgivelse af Rasilez HCT- tabletter er tiden for middel peak- plasmakoncentrationen under 1 time for aliskiren og 2, 5 timer for hydrochlorthiazid.
28 Aliskiren/ hydrochlorothiazide Following oral administration of Rasilez HCT tablets, the median peak plasma concentration time is within 1 hour for aliskiren and 2.5 hours for hydrochlorothiazide.
29 kombinationen, da de kun var synlige i minimal sværhedsgrad hos alle dyr.
29 6.
Talcum Hypromellose Macrogol Titandioxid (E171) Rød jernoxid (E172) Gul jernoxid (E172)
Talc Hypromellose Macrogol Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172)
Rasilez HCT 300 mg/ 12, 5 mg filmovertrukne tabletter
Rasilez HCT 300 mg/ 12.5 mg film-coated tablets
Hver filmovertrukken tablet indeholder 300 mg aliskiren (som hemifumarat) og 12, 5 mg hydrochlorthiazid.
Each film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 12.5 mg hydrochlorothiazide.
Violet- hvid, udadbuet, oval, filmovertrukken tablet, præget med ” CVI ” på den ene side og ” NVR ” på den anden.
Violet white, biconvex, ovaloid film-coated tablet imprinted with “ CVI” on one side and “ NVR” on the other.
Rasilez HCT 300 mg/ 12, 5 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt behandlet med aliskiren 300 mg eller hydrochlorthiazid 12, 5 mg anvendt alene eller med Rasilez HCT 150 mg/ 12, 5mg.
Rasilez HCT 300 mg / 12.5 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 300 mg or hydrochlorothiazide 12.5 mg alone or by Rasilez HCT 150 mg/ 12.5 mg.
32 Hvis blodtrykket ikke er under kontrol efter 2- 4 ugers behandling kan dosis titreres op til en maksimal daglig dosis på 300 mg/ 25 mg Rasilez HCT.
If blood pressure remains uncontrolled after 2-4 weeks of therapy, the dose may be titrated up to a maximum of Rasilez HCT 300 mg/ 25 mg daily.
Dosering ved erstatningsterapi Patienter, som får aliskiren og hydrochlorthiazid fra hver sin tablet, kan for nemhedens skyld skifte til Rasilez HCT med den samme dosis af hver komponent.
32 Posology as substitution therapy For convenience, patients receiving aliskiren and hydrochlorothiazide from separate tablets may be switched to a fixed combination tablet of Rasilez HCT containing the same component doses.
33 Intravaskulær væskemangel Symptomatisk hypotension kan forekomme hos patienter med væske - og/ eller saltmangel som et resultat af kraftig diuretikabehandling, diæt med begrænset saltindtag, diarré eller opkastning.
Intravascular volume depletion Symptomatic hypotension may occur in patients who are volume and/ or sodium depleted as a result of vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Elektrolytubalance Som for enhver patient, der modtager diuretikabehandling, skal der foretages en regelmæssig bestemmelse af serumelektrolytter med passende intervaller.
33 Electrolyte imbalance As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.
34 Der er ingen klinisk erfaring med Rasilez HCT til patienter med nedsat leverfunktion.
There is no clinical experience with Rasilez HCT in patients with hepatic impairment.
Moderate P- gp- hæmmere Samtidig administration af 300 mg aliskiren og 200 mg ketoconazol resulterede i en 76% stigning i aliskirens AUC, men P- gp- hæmmere som ketoconazol kan forventes at øge vævskoncentrationerne mere end plasmakoncentrationerne.
34 Moderate P-gp inhibitors Co-administration of aliskiren 300 mg with ketoconazole 200 mg resulted in a 76% increase in aliskiren AUC but P-gp inhibitors such as ketoconazole are expected to increase tissue concentrations more than plasma concentrations.
Omvendt, baseret på erfaringerne med anvendelsen af andre lægemidler, som påvirker renin- angiotensin- systemet (RAS), kan samtidig 35 brug af kaliumbesparende diuretika, kaliumtilskud, kaliumholdige salterstatninger eller andre lægemidler, som øger koncentrationen af kalium i serum (f. eks. heparin), føre til stigninger serumkalium.
Conversely, based on experience with the use of other medicinal products that blunt the renin-angiotensin system (RAS), concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin sodium) may lead to increases in serum potassium.
Lægemidler, der påvirkes af serumkaliumforstyrrelser:
35 Medicinal products affected by serum potassium disturbances:
36 Furosemid:
Furosemide:
Som for andre stoffer, der virker på renin - angiotensin- systemet, kan NSAID reducere aliskirens antihypertensive effekt.
In some patients with
Hos visse patienter med svækket nyrefunktion (dehydrerede patienter eller ældre patienter) kan samtidig administration af aliskiren og NSAID medføre en forværring af nyrefunktion, inklusive mulighed for akut nyresvigt, som sædvanligvis er reversibel.
36 compromised renal function (dehydrated patients or elderly patients) aliskiren given concomitantly with NSAIDs may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
37 lægemidlers renale udskillelse (f. eks. cyclofosfamid, methotrexat) og potentiere deres myelosuppressive virkninger.
37 4.6 Pregnancy and lactation
38 Diarré:
38 Serum potassium:
39 Hydrochlorthiazid Rapporterede bivirkninger (uanset forhold til lægemidlet) ved anvendelsen af hydrochlorthiazid alene omfatter:
39 Blood and lymphatic system disorders
Rasilez HCT kombinerer to antihypertensive komponenter til kontrol af blodtryk hos patienter med essentiel hypertension:
Rasilez HCT combines two antihypertensive compounds to control blood pressure in patients with essential hypertension:
41 Hydrochlorthiazid Thiaziddiuretikas virkningspunkt er primært i nyrens tubulus contortus distalis.
41 Hydrochlorothiazide The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule.